Geron Corporation (GERN) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Geron Corporation (GERN)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

2.94

-0.04 (-1.34%)

At close: Jan 14, 2025, 3:59 PM

2.91

-1.06%

After-hours Jan 14, 2025, 07:13 PM EST

undefined% (undefined)

Bid	2.88
Market Cap	1.78B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.32
PE Ratio (ttm)	-9.2
Forward PE	n/a
Analyst	Buy

Ask	2.94
Volume	10,880,316
Avg. Volume (20D)	10,456,729
Open	3.02
Previous Close	2.98
Day's Range	2.87 - 3.09
52-Week Range	1.64 - 5.34
Beta	undefined

About GERN

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes a...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 31, 1996

Employees 141

Stock Exchange NASDAQ

Ticker Symbol GERN

Website https://www.geron.com

Analyst Forecast

According to 10 analyst ratings, the average rating for GERN stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 137.69% from the latest price.

Buy 90.00%

Hold 10.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Geron Corporation is scheduled to release its earnings on Feb 26, 2025, before market opens.
Analysts project revenue of $60.27M, reflecting a 261.94K% YoY growth and earnings per share of -0.05, making a -44.44% decrease YoY.

Why Price Moved

5 months ago · Source

-7.14%

Geron shares are trading lower after the company a... Unlock content with Pro Subscription

5 months ago · Source

-1.28%

Geron shares are trading lower after the company announced the departure of CCO Anil Kapur.

News

6 days ago · zacks.com

Geron Stock Rallies More Than 60% in a Year: Here's Why

FDA's approval of GERN's Rytelo (imetelstat) for treating low- to intermediate-1 risk MDS drives the stock 61.1% higher in the past year.

3 weeks ago · businesswire.com

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggr...

1 month ago · businesswire.com

Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that...

1 month ago · businesswire.com

Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that members of the management team are scheduled to participate i...

1 month ago · seekingalpha.com

Geron: A Strong Launch And Financial Deals Make It Attractive

Geron exceeded expectations with $28.2mn in Q1 revenue, surpassing analyst estimates and showcasing strong physician feedback and market potential for imetelstat. Analysts are bullish, with H.C. Wainw...

2 months ago · businesswire.com

Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development

2 months ago · businesswire.com

Geron to Participate in the Stifel 2024 Healthcare Conference

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced members of the management team are scheduled to participate in a f...

2 months ago · seekingalpha.com

Geron: A Post Earnings And Funding Announcement Assessment

Geron Corporation's imetelstat, now branded as Rytelo, was finally approved by the FDA in June for treating lower risk myelodysplastic syndromes and has shown solid initial sales traction. The company...

2 months ago · seekingalpha.com

Geron Corporation (GERN) Q3 2024 Earnings Call Transcript

Geron Corporation (NASDAQ:GERN ) Q3 2024 Results Conference Call November 7, 2024 8:00 AM ET Company Participants Aron Feingold - Vice President of IR and Corporate Communication John Scarlett - Chair...

2 months ago · zacks.com

Geron (GERN) Reports Q3 Loss, Tops Revenue Estimates

Geron (GERN) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.08 per share a year ago.

2 months ago · businesswire.com

Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors

3 months ago · businesswire.com

Geron to Announce Third Quarter 2024 Financial Results on November 7, 2024

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its third quarter 2024 financial results and ...